Transcript Highlights:

• Our pharmaceuticals tend to go up and down.
• We started a pharmaceutical rebate program last year that's looking to save us $10 million this year,
• And, you know, we leverage the DGS contracting, you know, to get better costs for our pharmaceuticals
• examples that the report really illustrated were more people who, just with the current laws and regulations
• the report really illustrated were more people who just with with the current you know laws and regulations

Transcript Highlights:

• Well, that is analogous with this process of having a drug, a pharmaceutical preparation of some sort
• </c><00:18:43.480><c> preparation</c><00:18:44.000><c> of</c> a drug a pharmaceutical preparation of
• </c><00:19:25.559><c> preparation</c><00:19:26.120><c> that</c> critical pharmaceutical preparation that
• critical pharmaceutical preparation that they<00:19:26.440><c> need</c><00:19:26.880><c> and</c><00:
• </c><01:37:47.719><c> that</c><01:37:48.040><c> our</c><01:37:48.280><c> legal</c> and the regulation

Committee: Senate Health and Human Services

Transcript Highlights:

• act to amend Title 4 relative to the Louisiana State Lottery Commission to provide for rules and regulations

Bills: SR107 , SCR53 , SCR54 , SCR55 , SCR12 , HB167 , HB181 , HB243 , HB316 , HB321 , HB335 , HB492 , HB578 , HB624 , HB708 , HB864 , HB906 , HB968 , HB969 , HB978 , HB985 , HB1005 , HB1032 , HB1077 , HB1095 , HB1104 , HB1118 , HB1157 , HB1187 , HB1189 , HB1195 , HB1198 , HB1220 , HB221 , HCR58 , SB283 , SB338 , SB488 , SB520 , HB90 , HB127 , HB138 , HB150 , HB201 , HB268 , HB273 , HB285 , HB315 , HB354 , HB355 , HB360 , HB376 , HB445 , HB506 , HB606 , HB649 , HB665 , HB681 , HB721 , HB746 , HB757 , HB781 , HB835 , HB844 , HB857 , HB872 , HB886 , HB889 , HB892 , HB972 , HB982 , HB987 , HB1037 , HB1068 , HB1072 , HB1078 , HB1085 , HB1132 , HB1137 , HB1167 , HB1174 , HB1232 , HB1238 , SB68 , SB76 , SB149 , SB191 , SB196 , SB318 , SB162 , SB382 , SCR33 , SCR30 , SB112 , SB194 , SB307 , SB341 , SB346 , SB363 , SB495 , SB503 , SB507 , SB509 , SB513 , SB408 , SB131 , SB145 , SB333 , SB464 , SB466 , SB500 , SB35 , SB65 , SB215 , SB228 , SB246 , SB249 , SB268 , SB269 , SB282 , SB296 , SB312 , SB319 , SB323 , SB369 , SB431 , SB474 , SB484 , SB490 , SB492 , SB501 , HCR14 , HB537 , HB652 , HB653 , HB661 , HB726 , HB756 , HB851 , HB964 , HB966 , HB34 , HB35 , HB48 , HB474 , HB553 , HB758 , HB852 , HB10 , HB16 , HB36 , HB44 , HB46 , HB52 , HB61 , HB78 , HB98 , HB102 , HB124 , HB126 , HB131 , HB135 , HB141 , HB142 , HB164 , HB170 , HB171 , HB179 , HB194 , HB231 , HB245 , HB280 , HB292 , HB294 , HB297 , HB305 , HB336 , HB337 , HB351 , HB436 , HB594 , HB789 , HB956 , HB957 , HB995 , HB1040 , HB50 , HB117 , HB120 , HB122 , HB139 , HB148 , HB149 , HB185 , HB199 , HB247 , HB271 , HB286 , HB301 , HB358 , HB359 , HB384 , HB413 , HB428 , HB450 , HB462 , HB547 , HB613 , HB631 , HB657 , HB669 , HB675 , HB680 , HB691 , HB712 , HB716 , HB720 , HB723 , HB727 , HB728 , HB735 , HB747 , HB759 , HB825 , HB842 , HB845 , HB846 , HB903 , HB904 , HB907 , HB923 , HB929 , HB941 , HB962 , HB965 , HB1036 , HB287 , HB370 , HB515 , HB521 , HB570 , HB1200 , HB119 , HB129 , HB677 , HB850

Keywords: condolence resolution, memorial resolution, tribute, sympathy, Joel Parker Sr., Louisiana Senate, rodeo, cowboy, horse trainer, stock and rodeo producer, black cowboy, African American history, community recognition, funeral resolution, celebration of life, Lottie Stampede Arena, Easter Sunday Rodeo, ranching, plantation work, faith community

Bills: SB30 , SB30 , SB517 , SB1313 , SB1314 , SB1316 , SB1541 , SB1698 , SB1845 , SB1860 , SB2420 , SB2429

Committee: Senate State Affairs

Keywords: hemp, consumable hemp products, hemp beverages, cannabinoids, delta-9 THC, THC, cannabis, CBD, cannabigerol, synthetic cannabinoids, hemp flower, natural hemp flower, hemp biomass, hemp testing laboratory, hemp manufacturer, hemp distributor, hemp retailer, hemp carrier, consumer delivery, occupational license

Transcript Highlights:

• DCC's regulations, while prohibiting cartoon images, don't define that term.
• Patients deserve a rigorously tested medicine that is proven to be safe and regulated.
• Pharmacies and regulators are still in the process of implementing this new framework.
• regulations.
• This clarity matters to patients and to regulators.

Committee: House Business and Professions

Transcript Highlights:

• Madam Chair and Senator This bill is attempting to regulate more right.
• Senate Bill 96, Regulated child care zoning requirements.
• So there's a lot of regulations that go into keeping children safe.
• I just don't understand how we as a state can regulate the array The low spots.
• The DOT obviously is heavily regulated.

Bills: SB20 , SB53 , SB86 , SB96 , SB129

Committee: Senate Senate Health & Public Affairs

Keywords: prior authorization, pharmacy benefits manager, PBM, health insurer, prescription drugs, step therapy, formulary, auto-adjudication, electronic portal, appeals, medical necessity, serious mental illness, mental health, schizophrenia, bipolar disorder, major depression, substance use disorder, addiction treatment, cancer, autoimmune disorder

Transcript Highlights:

• market because it's over-regulated and heavily mandated in a manner that adds cost.
• And you know McKesson just happens to be in the pharmaceutical business.
• We firmly believe, and with the testimony you heard here is that regulation has a cost to it.
• It doesn't matter what you're regulating; it has a cost.
• Prices always come down because of the cost of regulation, and in this case, from what was given when

Bills: SB502 , SB513 , SB622 , SB670 , SB731 , SB732 , SB916 , SB961 , SB1122

Committee: Senate Health & Human Services

Transcript Highlights:

• We have got to rein in this unregulated or loosely regulated cottage industry that is running wide open
• It creates an early childhood interagency work group consisting of the agencies with a role in regulating
• There's a common theme that we're hearing: in the area of childcare, our governance and regulation are
• But still have that additional regulation where the Texas Medical Board is overseeing that the facility
• under Jordan Dixon in her department, has identified hundreds of barriers, which are rules and regulations

Bills: HB 1106 , HB3284 , HB541 , HB713 , HB1403 , HB1586 , HB1942 , HB2070 , HB2844 , HB2851 , HB3151 , HB3749 , HB3940 , HB3963 , HB4454 , HB4466 , HB4795 , HB5154 , HB5394 , SB1357 , HB 1052 , HB4099 , HB4638 , HB5147

Committee: Senate Health & Human Services

Transcript Highlights:

• In the health care space, we're trying to hold pharmaceutical companies accountable and reduce the cost
• ><c> to</c><00:02:13.080><c> hold</c> space, we're trying to hold space, we're trying to hold pharmaceutical
• <00:02:13.920><c> companies</c><00:02:14.520><c> accountable</c><00:02:15.280><c> and</c> pharmaceutical
• companies accountable and pharmaceutical companies accountable and reduce<00:02:16.360><c> the</c><00

Transcript Highlights:

• But unfortunately, in the last couple of years, there have been practices by some pharmaceutical companies
• actions, and following the lead of 21 states or 20-some-odd states, this bill would prohibit... ...pharmaceutical
• believe that this is something that we need to put in place because of the practices of certain pharmaceutical
• I believe that creating these limitations to what pharmaceutical companies, et cetera, can do would actually
• concerned, the reason why I believe this is necessary is precisely because the actions of some pharmaceutical

Committee: Senate Health

Summary: The Health Committee met to consider a series of bills, many of them repeat proposals from prior sessions. Early measures included S.11 on disclosure for non-invasive prenatal screening, S.92 allowing redaction of certain physician names from birth certificates, S.135 creating practical support grants for abortion care, S.428A requiring chain restaurants to label high-sodium menu items, S.555 prohibiting visual images of people undergoing medical treatment without consent, and S.1614A establishing presumptive Medicaid eligibility for people leaving incarceration. The committee also advanced S.1438A to create an abortion clinical training program, S.1468 on access to medical records and limiting copy charges to actual cost, S.1619 expanding pharmacists’ authority to order and administer certain tests, and S.1714 banning the use of “excited delirium” as a diagnosis or cause of death. A substantial portion of the meeting focused on S.1633A, which would add protections for sensitive health information and allow patients to restrict disclosure of specified categories of data. One senator argued the bill could hinder care by limiting access to complete records, especially in emergencies, while supporters said the measure was needed to protect patients and providers from legal action by other states or the federal government, particularly in reproductive health cases. Staff clarified that the bill would allow segregation of specific sensitive data rather than locking an entire record. The committee also discussed S.1913, a 340B prescription drug anti-discrimination bill; supporters said it would protect safety-net providers and federally qualified health centers from pharmaceutical company practices, while one senator raised concerns about broad state intervention in a federal program. Additional bills advanced included S.5981 establishing a comprehensive sexual and reproductive health program, S.6178 directing a sickle cell disparity study, S.7457 permitting cremation or natural organic reduction for certain unclaimed decedents, S.7541 moving up reporting timelines for licensed home care services agencies, and S.8257A directing an alternative payment methodology for federally qualified health centers to support fertility care. Most bills were moved by committee vote, generally with some opposition or without recommendation, and were referred to first reading, rules, or finance as appropriate.

Transcript Highlights:

• Anything that goes into your body, any pharmaceuticals, can have side effects and that includes the MMR
• So we provide the food safety regulations for meat and milk.
• This division also regulates EMS providers and companies, oversees trauma system coordination between
• HHSC regulates healthcare providers, professions, and facilities. to protect the health and safety of
• And we underwent a line-by-line review of every regulation.

Committee: House Public Health

Transcript Highlights:

• And that is a that is a list of of of pharmaceuticals that pharmaceuticals that pharmaceuticals that
• . retail pharmaceuticals. retail pharmaceuticals.
• industry formulary, the pharmaceutical industry formulary, the pharmaceutical industry either has to
• That's the way it used to be before the pharmaceutical used to be before the pharmaceutical used to be
• before the pharmaceutical benefit managers came into benefit managers came into benefit managers came

Bills: SCR 13 , SCR 24 , SB 1 , SB 12 , SB 15 , SB 17 , SB 24 , SB 57 , SB 65 , SB 213 , SB 371 , SB 372 , SB 378 , SB 379 , SB 388 , SB 400 , SB 402 , SB 427 , SB 495 , SB 499 , SB 502 , SB 509 , SB 535 , SB 583 , SB 610 , SB 621 , SB 650 , SB 706 , SB 740 , SB 840 , SB 854 , SB 856 , SB 875 , SB 893 , SB 918 , SB 925 , SB 974 , SB 995 , SB 1006 , SB 1018 , SB 1025 , SB 1061 , SB 1073 , SB 1106 , SB 1121 , SB 1194 , SB 1252 , SB 1253 , SB 1268 , SB 1300 , SB 1343 , SB 1362 , SB 1447 , SJR 36 , SJR 12 , SJR 57 , SCR 25 , SCR 22 , SCR 12 , SCR 24 , SCR 8 , SB 565 , SB 372 , SB 765 , SB 62 , SB 666 , SB 707 , SB 888 , SB 687 , SB 847 , SB 1248 , SB 740 , SB 14 , SB 1006 , SB 504 , SB 925 , SB 1121 , SB 995 , SB 857 , SB 305 , SB 296 , SB 284 , SB 815 , SB 1379 , SB 1300 , SB 1497 , SB 1499 , SB 1498 , SB 1061 , SB 65 , SB 241 , SB 304 , SB 402 , SB 499 , SB 621 , SB 974 , SB 1023 , SB 1024 , SB 1025 , SB 1106 , SB 686 , SB 112 , SB 371 , SB 204 , SB 400 , SB 609 , SB 1447 , SB 670 , SB 502 , SB 427 , SB 850 , SB 854 , SB 413 , SB 1555 , SB 1362 , SB 1346 , SB 1033 , SB 1220 , SB 1073 , SB 810 , SB 987 , SB 1539 , SB 893 , SB 447 , SB 875 , SB 406 , SB 509 , SB 985 , SB 965 , SB 1119 , SB 1505 , SB 24 , SB 57 , SB 1194 , SB 1253 , SB 1215 , SB 1532 , SB 1268 , SB 1302 , SB 856 , SB 650 , SB 583 , SB 673 , SB 840 , SB 213 , SB 681 , SB 1172 , SB 1252 , SB 378 , SB 610 , SB 918 , SB 1343 , SB 608 , SB 487 , SB 955 , SB 957 , SB 988 , SB 990 , SB 1019 , SB 1021 , SB 1120 , SB 251 , SB 958 , SB 535 , SB 761 , SB 1 , SB 541 , SB 315 , SB 379 , SB 1018 , SB 1737 , SB 266 , SB 1415 , SB 57 , SB 499 , SB 974 , SB 1025 , SB 1061 , SB 1268 , SR 302 , SR 303 , SR 304 , SR 305 , SB 30 , SB 1333 , SB 1666 , SB 30 , SB 1333 , SB 1666

Transcript Highlights:

• Um, and we had emotionally regulate.
• </c> glove with pharmaceutical manufacturers. glove with pharmaceutical manufacturers.
• </c><01:16:59.440><c> on</c> mentioned uh federal regulations on mentioned uh federal regulations on
• </c> representative of peers that regulate representative of peers that regulate the<01:41:02.719><c>
• It's schools are very well regulated.

Committee: House Health, Human Services and Elderly Affairs

Transcript Highlights:

• I wish we had the ability to set the spending targets on pharmaceutical drugs.
• What changed were regulations. As he lost his insurance, he could not afford the necessary care.
• The fourth point is that the pharmaceutical cost of prescription drugs needs to be reined in.
• , the federal government had made these regulations long ago—the cat's sort of out of the bag, so to
• Which, unfortunately, I wish, in hindsight, the federal government had made these regulations long ago

Summary: The joint informational hearing focused on the cost of uncertainty in California health care, especially the effects of federal policy changes on coverage, access, and affordability. Opening remarks from committee leaders and members emphasized that California’s uninsured rate had fallen to historic lows under the Affordable Care Act and state policies, but that the expiration of enhanced federal subsidies, H.R. 1, and other federal regulatory changes could reverse those gains. Members repeatedly cited rising premiums, skipped care, medical debt, and the strain on low-wage workers, families, clinics, hospitals, and public programs. The first panel reviewed the federal landscape and state response. A federal policy analyst described the ACA’s coverage gains and consumer protections, then outlined current threats: H.R. 1’s Medicaid and marketplace cuts, the end of enhanced premium tax credits, shorter open enrollment, more verification requirements, and changes affecting preventive services and vaccines. Covered California reported that the loss of subsidies is expected to nearly double average monthly premiums, reduce enrollment, and push more consumers into bronze plans with higher deductibles; it also noted that California’s $190 million affordability fund is helping the lowest-income enrollees. HCAI’s Office of Health Care Affordability explained its work on spending targets, market consolidation review, and primary care investment, saying the goal is to slow spending growth rather than impose price caps. Committee members pressed witnesses on the practical effects of bronze plans, administrative burdens, immigration-related disenrollment, provider taxes, uncompensated care, and whether California can sustain current coverage levels without new revenue. Witnesses said bronze plans preserve essential benefits but shift more costs to consumers, and that H.R. 1’s verification and auto-renewal changes will likely reduce enrollment. They also said provider tax reductions could significantly weaken state financing over time, and that higher uninsured rates may increase uncompensated care and pressure premiums elsewhere in the system. The second panel, featuring UC Berkeley Labor Center and California Health Care Foundation experts, highlighted broader affordability problems across job-based coverage and Medi-Cal, citing medical debt, skipped care, and the role of underlying system costs, administrative waste, and lack of competition. They pointed to medical debt relief efforts such as Los Angeles County’s program as a short-term mitigation strategy while the Legislature considers longer-term policy and budget responses.

Transcript Highlights:

• benefit manager practices in the state to ensure transparency and fairness for consumers and in the pharmaceutical
• Thanks for being here. fairness for consumers and in fairness for consumers and in pharmaceutical<00:
• </c><00:18:15.679><c> lower</c><00:18:16.000><c> drug</c><00:18:16.400><c> costs</c> pharmaceutical sectors
• . lower drug costs pharmaceutical sectors. lower drug costs for<00:18:17.120><c> patient</c><00:18:17.600
• My name is Tanya Neil, and I'm with the Pharmaceutical Care Management Trade Association.

Committee: House Health

Summary: The Committee on Health met on April 11, 2025, and heard testimony on a series of Senate concurrent and Senate resolution measures focused on health system oversight, workforce standards, and access to care. Topics included an auditor study on mandated insurance coverage for intravenous ketamine therapy for depression (SCR 8 SD1), a working group on prior authorization reform (STR 10 SD2), a task force on minimum professional standards for community health worker training (STR 16 SD1), a pharmacy benefit manager reform working group (SCR 69 SD1), a pharmacy reimbursement working group (STR 70 SD1), an aeromedical services working group (STR 86 SD1), a catchment-water feasibility study for business use (STR 118 SD1), an auditor study on mandatory coverage for continuous glucose monitors (STR 120 SD1), and a resolution encouraging reduced use of disposable surgical equipment and more sustainable health care practices (STR 194 SD1). Testimony was generally supportive across the measures, with several agencies and organizations noting the need to address complex health policy issues and improve access, transparency, and sustainability. For STR 16 SD1, community health worker advocates strongly supported the resolution but asked for amendments to include the Hawaii Community Health Worker Association on the task force and to require that at least half of the task force members be community health workers. For the PBM-related measures, SHPDA said it was willing to convene the work group and described the issue as complex, while the Pharmaceutical Care Management Association asked that PBMs be included in the working group. For STR 10 SD2, SHPDA supported the effort to reduce prior authorization burdens and said the process is a "black box" that needs reform; the chair later noted the administration’s commitment to the issue. For STR 86 SD1, the Department of Health supported the aeromed working group, and the chair proposed a House Draft 1 with technical changes and added representation from independent provider operators. In decision making, the committee adopted the chair’s recommendations on all measures considered. SCR 8 SD1 was passed as is. STR 10 SD2 was deferred. STR 16 SD1, STR 70 SD1, STR 118 SD1, STR 120 SD1, and STR 194 SD1 were passed as is. SCR 69 SD1 was passed with amendments, and STR 86 SD1 was passed with amendments. The meeting concluded with adjournment after all votes were taken.

Transcript Highlights:

• is a combination of all the regulated operations and professional licenses issued by HHSC.
• There are more than 65,000 operations regulated over 38 different provider types.
• We're focused on the licensing and the regulation of the provider facility in those hospitals.
• In addition, we have active litigation against several major pharmaceutical companies.
• We have active litigation against several major pharmaceutical companies.

Summary: The Senate Finance Committee met to hear interim charges on higher education transparency and on preventing fraud, waste, and abuse in state government. The chair emphasized accountability for taxpayer dollars and asked witnesses to address financial reporting, audit practices, and whether more frequent or comprehensive audits would improve oversight. Legislative Budget Board staff described how public university systems and most community colleges respond to requests about internal audit practices, noting that university systems generally follow a similar annual audit timeline and that community colleges use a more varied mix of internal and external audit arrangements. Members focused on gaps in reporting, especially Texas Southern University’s missing submissions for several years and Collin County Community College’s nonresponse to the LBB survey. The State Auditor’s Office then outlined its higher education audit work, including mandatory statewide single audits, DEI compliance audits, HUB and State Use Program audits, benefits proportional audits, and discretionary audits based on risk. The auditor said the office has released 43 higher-ed audit reports since fiscal year 2021 and has two audits in progress, and explained that internal audit reports from institutions help guide future audit selection. Senators pressed the office on the lack of enforcement authority, the value of internal auditors at each institution, and whether community colleges should have more standardized reporting and audit requirements. The auditor and general counsel said the SAO can refer suspected fraud to law enforcement but cannot itself enforce findings, while several senators suggested stronger clawback authority and more robust internal audit structures. The Texas Higher Education Coordinating Board explained that it collects annual financial reports, sources-and-uses data, and community college finance reports, and uses them for funding formulas and other reporting. It also trains governing board members and said it has limited regulatory authority, though community colleges must certify compliance annually and can lose eligibility for state funds if they do not. Members questioned the reliability of self-attested data, the adequacy of board training, and whether a single reporting structure would be more efficient. During public testimony, a ScholarShot representative argued for clearer, student-facing financial transparency so students can see total cost of attendance and the gap they must cover before enrolling.

Transcript Highlights:

• :30.159><c> authority</c><00:23:30.559><c> to</c> in our regulations the authority to in our regulations
• ,</c><00:26:25.200><c> but</c> talks about limits and regulation, but talks about limits and regulation
• </c><01:06:19.280><c> cannabis</c> enforcement tool in regulating cannabis enforcement tool in regulating
• Regulation. Um, initially I would like Regulation.
• </c> legalize and regulate cannabis now. legalize and regulate cannabis now.

Summary: The committee first heard SB 888, which would bar operators of smart household security devices from sharing user data with law enforcement unless the user consents or police obtain a warrant. DCCA’s Office of Consumer Protection offered comments and Judiciary submitted written support. Several individuals also submitted written support. The committee recommended passage with amendments clarifying that the Office of Consumer Protection may enforce violations and adopting Judiciary’s recommended changes, while also deferring the effective date to July 1, 2050. The motion passed unanimously among members present, with one senator excused. The committee then took up SB 2777 on insurance disclosures. The bill would require authorized insurers to disclose claim-handling data to consumers, including claims open at the start of a period, closed with payment, closed without payment, and open at the end of the period. The committee described amendments to clarify the bill, remove a requirement for the DCCA insurance division to handle publication, and defer the effective date to July 1, 2050. The measure was passed with amendments and the recommendation was adopted, with one member voting no and another excused. In a joint Commerce and Consumer Protection/Judiciary hearing on SP2738 relating to tax haven abuse, the Department of Taxation offered comments and the Tax Foundation testified in opposition, arguing the state should rely on IRS audits and existing worldwide reporting rules rather than create a separate state approach. Other written testimony was noted in both support and opposition. The committees recommended passage with amendments adopting Taxation’s technical changes and deferring the effective date to July 1, 2050; the recommendation was adopted, with one senator noting reservations. The joint hearing then moved to health-related bills, including SB 2690 on primary care spending, SB 3103 on energy assistance, SB 3137 on Department of Health authority over food, drugs, and cosmetics, SB 3164 on child welfare service organizations, and SB 3206 on cannabinoids. SB 2690 drew strong support from physicians and advocates who said it would address primary care shortages, especially on neighbor islands, while HMSA and others warned a fixed spending percentage could raise costs and suggested a working group. SB 3164 drew support from child welfare providers and opposition from the Attorney General over indemnification language, and SB 3206 drew mixed testimony: state agencies raised federal-law and vagueness concerns, while hemp and cannabis advocates and some farmers supported the measure and urged broader legalization or amendments.

Transcript Highlights:

• authority to pharmacists, particularly when it comes to prescribing or maneuvering and changing pharmaceutical
• This is a... ...pharmaceutical therapy for patients.
• And in the news business, we care about the actions of the regulator and not necessarily the regulated
• And in the news business, we care about the actions of the regulator and not necessarily the regulated
• As of today, 20 states have brought their state statutes in line with federal regulations.

Summary: The committee heard testimony on several bills, beginning with House Bill 2333, which would expand protections for elected officials, candidates, executive state officers, election officials, and criminal justice participants by allowing address confidentiality, redacting campaign and property records, increasing some penalties for threats, and authorizing security assessments and reimbursement for personal security measures. The prime sponsor and supporters described rising political violence and personal threats, while opponents and agency staff raised concerns about implementation, constitutional issues, public-records transparency, costs, and whether the bill would actually prevent determined actors from finding addresses through other sources. The Secretary of State’s office, county officials, and the Public Disclosure Commission said the bill would create major logistical and fiscal challenges, while prosecutors, judges, and advocacy groups testified that the protections were needed for safety and retention in public service. House Bill 2176 would make collaborative drug therapy agreements confidential under the Public Records Act except when the agreement is the basis for a disciplinary action, in which case only relevant information would be disclosed with personal information redacted. The sponsor and supporters, including pharmacists, physicians, and reproductive-health advocates, said the bill would protect clinicians from harassment and out-of-state targeting while preserving accountability for misconduct. News media representatives and open-government advocates said the underlying agreements should remain accessible only in limited circumstances and emphasized the balance between privacy and transparency. Committee members also discussed how the bill would affect access to the agreements and the scope of disclosure. House Bill 2120 would eliminate two JLARC reporting requirements: the biennial report on municipal lodging-tax revenues and the periodic evaluation of the training benefits program. The bill’s sponsor and JLARC leadership described it as a cost-saving measure that would free staff for other audits, while the hospitality industry supported tourism funding but warned that the lodging-tax report provides useful oversight and accountability. The committee also received staff briefings on House Bill 2244, which would implement multiple Public Records Exemptions Accountability Committee recommendations by changing confidentiality rules in 13 areas, including grand jury reports, accident reports, driver case records, certain health and social-service records, corporate interrogatories, family court files, and other records.

Transcript Highlights:

• Committee will be meeting upon adjournment today to hear two sunset reviews, which are the Veterinary Pharmaceutical
• 23:14.960><c> Veterary</c> reviews uh which are the Veterary reviews uh which are the Veterary Pharmaceutical
• <00:23:16.159><c> Advisory</c><00:23:16.720><c> Committee</c><00:23:17.200><c> and</c> Pharmaceutical
• Advisory Committee and Pharmaceutical Advisory Committee and the<00:23:17.919><c> Forest</c><00:23:18.400

Transcript Highlights:

• They enforce and regulate the clinicians.
• :47:51.200><c> that</c><00:47:51.440><c> is</c> introducing any regulation that is introducing any regulation
• </c> pharmaceutical interventions, and more. pharmaceutical interventions, and more.
• We don't regulate Medicaid.
• </c> projections for these pharmaceuticals. projections for these pharmaceuticals.

Committee: Senate Health and Human Services